Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; water for injections; sodium hydroxide; sulfuric acid - vincristine is used primarily in the treatment of acute leukaemia, usually as a component of various chemotherapeutic regimens. it has also been used as part of combination therapy in the treatment of hodgkin's disease, non-hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung and gynaecological tumours of childhood. vincristine may be useful in patients with true idiopathic thrombocytopenic purpura resistant to the usual treatment, but not recommended as primary treatment for this disorder

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

andres pintaluba s.a. - colistin (as sulfate) - premix for med.feedstuffs - 1,200,000 international unit - colistin - porcine - antibiotics

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

andres pintaluba s.a. - colistin - premix for medicated feeding stuff - 1,200,000 international unit(s)/gram - colistin - pigs - antibiotics

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection - excipient ingredients: mannitol; water for injections; sulfuric acid; sodium hydroxide - vincristine sulphate is used either alone or in conjunction with other oncolytic drugs for the treatment of: leukaemias, malignant lymphomas, multiple myeloma, breast carcinoma, small cell bronchogenic carcinoma, head and neck carcinoma, soft tissue sacomas, paediatric solid tumours and idiopathic thrombocytopenic purpura.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection - excipient ingredients: sodium hydroxide; sulfuric acid; mannitol; water for injections - vincristine sulfate solution for injection is used in the treatment of cancers of the blood (e.g. leukaemia or lymphomas), breast, head and neck or lung. it may be used to treat multiple myeloma (a cancer of plasma cells) and it may also be used in the treatment of some cancers in children. it may be used in a blood disorder known as idiopathic thrombocytopenic purpura (itp) after other treatments have not been successful. vincristine sulfate solution for injection may be given alone or in combination with other anti-cancer medicines.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection - excipient ingredients: mannitol; water for injections; sodium hydroxide; sulfuric acid - vincristine sulfate is indicated in the treatment of acute leukemia. it has also been used in combination with other antineoplastic drugs in hodgkin's disease, soft-tissue sarcoma, bony-tissue sarcoma, sarcomas of specialized structures, breast cancer, small cell cancer of the lung, cancer of uterine cervix, malignant melanoma, colorectal cancer, non-hodgkin's lymphoma, and wilm's tumor.

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

hospira uk ltd - vincristine sulfate - solution for injection - 5 mg/5ml

Spojené štáty - angličtina - NLM (National Library of Medicine)

endo pharmaceuticals, inc. - colistin sulfate (unii: wp15dxu577) (colistin - unii:z67x93hjg1), neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), thonzonium bromide (unii: ji2b19cr0r) (thonzonium - unii:z05ze98fv8), hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj) - cortisporin® tc otic is indicated for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics. this product is contraindicated in those individuals who have shown hypersensitivity to any of its components. this product should not be used if the external auditory canal disorder is suspected or known to be due to cutaneous viral infection (e.g., herpes simplex virus or varicella zoster virus).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sodium hydroxide; sulfuric acid; water for injections - the treatment of acute leukaemia, usually as a component of various chemotherapeutic regimens. it has also been used as part of combination therapy in the treatment of hodgkins disease, non-hodgkin?s malignant lymphomas, rhabdomyosarcoma, neuroblastoma, wilm?s tumour, osteogenic sarcoma, mycosis fungoides, ewing?s sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung and gynaecological tumours of childhood. vincristine may be useful in patients with true idiopathic thrombocytopenic purpura resistant to the usual treatment, but not recommended as primary treatment for this disorder.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - vincristine sulfate 1 mg/ml;  ;   - solution for injection - 1 mg/ml - active: vincristine sulfate 1 mg/ml     excipient: mannitol sodium hydroxide sulfuric acid water for injection